Nuvation Bio Inc.
NUVB-WT
New York Stock Exchange0.07
USD
+0.00
- -
Nuvation Bio Inc.
NUVB-WT
(New York Stock Exchange)
Recent
price
0.07
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Nuvation Bio Inc. (NUVB-WT) is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines targeting oncology and oncology-adjacent diseases. The company offers a pipeline of small molecule drug candidates, including taletrectinib, a next-generation ROS1 and NTRK inhibitor for non-small cell lung cancer and solid tumors; NUV-868, a BET inhibitor for solid tumors and hematologic malignancies; and NUV-1511, a CDK7 inhibitor for various cancers, along with earlier-stage assets such as NUV-1001 and antibody-drug conjugates. These products emphasize targeted therapies designed to address unmet needs in precision medicine through selective inhibition mechanisms and combination potential. Founded in 2018 and headquartered in New York, New York, Nuvation Bio operates primarily in the United States with a global clinical footprint spanning North America, Europe, and Asia-Pacific regions, serving patients and healthcare providers in the oncology sector. The company targets advanced solid tumors and blood cancers, positioning itself within the competitive biopharma landscape of precision oncology innovators. In recent developments, Nuvation Bio reported positive topline data from the TRUST-IV phase 2 trial of taletrectinib in October 2025, demonstrating robust efficacy in ROS1-positive NSCLC patients, prompting plans for regulatory submissions in 2026. The company also advanced NUV-868 into a phase 1b expansion study in September 2025, combining it with PARP inhibitors for ovarian cancer, and secured a strategic research collaboration with a leading academic institution for novel ADC technologies in late 2024. These milestones reflect ongoing pipeline progression amid a challenging biotech funding environment, with no major acquisitions or name changes reported in the last two years.